CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

BucillamineWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug3254 e-Psychotherapy Wiki 0.71
drug2122 Placebo Wiki 0.04

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D001008 Anxiety Disorders NIH 0.11
D003863 Depression, NIH 0.10

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients With Mild-Moderate COVID-19

This is a Phase 3, multi-center, randomized, double blind, placebo controlled, clinical study of bucillamine (2 dosage levels) in patients with mild-moderate COVID-19. Patients will be randomized 1:1:1 to receive bucillamine 100 mg 3 times a day (TID), bucillamine 200 mg TID or placebo TID for up to 14 days. After the first interim analysis when a single dose is selected, patients will then be randomized 2:1 to the selected bucillamine dose or placebo The study will be overseen by an independent Data and Safety Monitoring Board (DSMB). Up to 10 centers in the United States will conduct this study. Up to 1000 patients will be enrolled in this study. Patients will participate in the study approximately 45 days.

NCT04504734 Covid19 Drug: Bucillamine Drug: Placebo Drug: Bucillamine

Primary Outcomes

Description: Proportion of patients meeting a composite endpoint of hospitalization or death

Measure: Efficacy: Frequency of hospitalization or death

Time: From time of first dose through Day 28 following randomization

Secondary Outcomes

Description: Number of adverse events

Measure: Safety: Changes in adverse events from baseline to end of study

Time: From time of first dose through Day 28 following randomization

2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients With Mild-Moderate COVID-19

This is a Phase 3, multi-center, randomized, double blind, placebo controlled, clinical study of bucillamine (2 dosage levels) in patients with mild-moderate COVID-19. Patients will be randomized 1:1:1 to receive bucillamine 100 mg 3 times a day (TID), bucillamine 200 mg TID or placebo TID for up to 14 days. After the first interim analysis when a single dose is selected, patients will then be randomized 2:1 to the selected bucillamine dose or placebo The study will be overseen by an independent Data and Safety Monitoring Board (DSMB). Up to 10 centers in the United States will conduct this study. Up to 1000 patients will be enrolled in this study. Patients will participate in the study approximately 45 days.

NCT04504734 Covid19 Drug: Bucillamine Drug: Placebo Drug: Bucillamine

Primary Outcomes

Description: Proportion of patients meeting a composite endpoint of hospitalization or death

Measure: Efficacy: Frequency of hospitalization or death

Time: From time of first dose through Day 28 following randomization

Secondary Outcomes

Description: Number of adverse events

Measure: Safety: Changes in adverse events from baseline to end of study

Time: From time of first dose through Day 28 following randomization

No related HPO nodes (Using clinical trials)